The combined therapy resulted in a stronger reduction of GBM aggressiveness when compared to TMZ or approved PDGFRβ and EGFR inhibitors (imatinib, gefitinib, and cetuximab) [50]. This evidence concerns the gene EGFR and glioblastoma.